Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer
NCT ID: NCT01074684
Last Updated: 2023-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
959 participants
OBSERVATIONAL
2010-01-31
2021-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3
NCT03488134
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
NCT04948437
Observational Study on Thyroid Tumors and EvaLuation of the roLe of New pOntential Predictive/Prognostic Factors
NCT07064369
Recurrence in Patients With Differentiated Thyroid Cancer
NCT06154863
Differentiation of Benign From Malignant Thyroid Nodules Using Diffuse Reflectance Spectroscopy
NCT07124065
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Indication for surgery
* Age \> 18 years
* Signed informed consent for surgery
* Signed informed consent for data collection
Exclusion Criteria
* Clinical or radiologic evidence of locally advanced tumor
* Clinical or radiologic evidence of metastatic lymph nodes or distant metastases
* Nonpalpable nodes
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute, Naples
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luciano Pezzulo, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute, Naples
Maria Grazia Chiofalo, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute, Naples
Massimo Di Maio, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute, Naples
Francesco Perrone, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute, Naples
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Università di Cagliari
Cagliari, , Italy
Azienda Ospedaliera Unviersitaria Careggi - Firenze
Florence, , Italy
ASL TO/4 Ospedale di Ivrea
Ivrea, , Italy
Istituto Nazionale dei Tumori
Napoli, , Italy
Azienda Ospedaliera Universitaria di Padova
Padua, , Italy
Università Cattolica del Sacro Cuore di Roma Policlinico Gemelli
Roma, , Italy
Ospedale di Taormina
Taormina, , Italy
Università degli studi di Perugia - Sede di Terni
Terni, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TIR-2009-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.